Description
+ Include: 9 videos + 10 pdfs, size: 7.58 GB
+ Target Audience: oncologist
+ Sample video: contact me for sample video
+ Information:
- Start date 20 May 2023
- End date 20 May 2023
- Location Dubai, United Arab Emirates
Learning objectives
- Understanding the function and biology of CDK4-6 in malignant breast cancer cells
- Information and in-depth discussion on the state of the art and emerging therapeutic strategies integrating CDK4-6 inhibition in breast cancer, both in the metastatic setting
- Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of CDK4-6 inhibition
- Providing an outlook of potential integration of CDK 4-6 inhibitors in the adjuvant setting
- Discussing clinical cancer cases to integrate use of CDK 4-6 inhibitors in clinical practice
+ Topics:
Programme.pdf
Session 1 Cont Clinical cases of high-risk patients with early HR positive HER2 negative breast cancer candidate to adjuvant CDK4-6 inhibitors Balancing efficacy and toxicity.mp4
Session 1 Cont Clinical cases of high-risk patients with early HR positive HER2 negative breast cancer candidate to adjuvant CDK4-6 inhibitors Balancing efficacy and toxicity.pdf
Session 1 Integrating CDK4-6 inhibitors in patients with early HR positive HER2 negative breast cancer Successes and failures.mp4
Session 1 Integrating CDK4-6 inhibitors in patients with early HR positive HER2 negative breast cancer Successes and failures.pdf
Session 1 Ongoing clinical studies on CDK4-6 inhibition in early HR positive HER2 negative breast cancer.mp4
Session 1 Ongoing clinical studies on CDK4-6 inhibition in early HR positive HER2 negative breast cancer.pdf
Session 1 Risk stratification in HR positive HER2 negative early breast cancer Lessons from neoadjuvant and adjuvant setting.mp4
Session 1 Risk stratification in HR positive HER2 negative early breast cancer Lessons from neoadjuvant and adjuvant setting.pdf
Session 2 CDK4-6 inhibition in patients with metastatic HR positive HER2 negative breast cancer Benefit in endocrine resistant disease.mp4
Session 2 CDK4-6 inhibition in patients with metastatic HR positive HER2 negative breast cancer Benefit in endocrine resistant disease.pdf
Session 2 Emerging data on new agents and new combinations in endocrine resistant disease.mp4
Session 2 Emerging data on new agents and new combinations in endocrine resistant disease.pdf
Session 3 CDK4-6 inhibitors beyond CDK4-6 inhibitors in metastatic setting.mp4
Session 3 CDK4-6 inhibitors beyond CDK4-6 inhibitors in metastatic setting.pdf
Session 3 Role of CD 4-6 inhibitors across enriched molecular subgroup.mp4
Session 3 Role of CD 4-6 inhibitors across enriched molecular subgroup.pdf
Welcome and introduction.mp4
Welcome and introduction.pdf
Reviews
There are no reviews yet.